Search Results
All Content Formulary Only Other ContentWe have found 11 results when searching "Guselkumab"
PATHWAY
Psoriatic Arthritis : Treatment of Psoriatic arthritis with biologics and targeted synthetic DMARDs
Biologic therapies may be initiated by rheumatologists in patients who have not responded to conventional DMARDs in line with British Society for Rheumatology guidance.
PATHWAY
Psoriasis : Biologic treatment of psoriasis with psoriatic arthritis
PATHWAY
Psoriasis : Biologic treatment of chronic plaque psoriasis
DOCUMENT
13/05/2026 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 13 May 2026 Page 1 of 15 East Region Formulary Committee Minutes Date: 13 May 2026 Time: 2.00pm – 4:20pm Location: MS Teams Present: Mona Boriceanu Advanced N...
DOCUMENT
12/11/2025 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 12 November 2025 Page 1 of 10 East Region Formulary Committee Minutes Date: 12 November 2025 Time: 2.00pm – 4:00pm Location: MS Teams Present: Malcolm Clubb ...
DOCUMENT
24/11/2021 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 24 November 2021 Page 1 of 24 East Region Formulary Committee Minutes Date: 24 November 2021 Time: 2pm – 4pm Location: MS Teams Present: Jane Browning Lead P...
FORMULARY DECISION
Guselkumab : Tremfya
SMC2848 : Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, ...
FORMULARY DECISION
Guselkumab : Tremfya
SMC2850 : For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy o...
FORMULARY DECISION
Guselkumab : Tremfya
1340/18 : Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy